ReviewFrontiers in bioengineering and biotechnology2020
Automation, Monitoring, and Standardization of Cell Product Manufacturing.
Review in Frontiers in bioengineering and biotechnology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 42 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
42 citing papers in PubMed.
- Coarse-graining analysis for non-invasive, label-free, and quantitative evaluation of undulating motion in cultured oral mucosa epithelial cell sheets.Regenerative therapy · 2026Article
- Performance of a modular robotic cluster matches skilled human operators for complex cell therapy manufacturing tasks.International journal of pharmaceutics: X · 2026Article
- Robotic handling preserves iPSC-derived vascular smooth muscle cell differentiation.Materials today. Bio · 2026Article
- Patient-Derived 3D Heart-On-a-Chip Model of Dilated Cardiomyopathy With Embedded Bead-Based Mapping of Tissue Contractility.Advanced healthcare materials · 2026Article
- Stem cell-based therapies for neuroretinal degeneration: current landscape and future perspectives.Stem cells translational medicine · 2026Review
- Exploring a Flow Cytometry-Based CFU Assay for Functional Assessment of Human HSPCs: a Robust Alternative to Morphological Colony Evaluation.Stem cell reviews and reports · 2026Article
- Biomimetic electrospun scaffolds for engineered heart tissue: from design parameters to drug testing platforms.Frontiers in bioengineering and biotechnology · 2026Review
- Automated Covalent Microcontact Bioprinting of Lubricant-Infused Microarrays for Biological Assays.Small (Weinheim an der Bergstrasse, Germany) · 2025Article
- An integrated platform for liquid handling and cell imaging in life science applications.Nature communications · 2025Article
- Alginate oligosaccharides in the food industry: emerging functional roles, health benefits, and technological applications - Review.Food chemistry: X · 2025Review
- Advancements and Applications of Split Technology in CRISPR/Cas12a: Transforming Molecular Diagnostics and Biosensing.Biosensors · 2025Review
- Machine learning aided UV absorbance spectroscopy for microbial contamination in cell therapy products.Scientific reports · 2025Article
- CGT 4.0: a distant dream or inevitable future? Smart process automation is critical to make efficient scalability of CGT manufacturing a reality.Frontiers in bioengineering and biotechnology · 2025Article
- Development of Automated Systems for Cell Therapy.Advances in experimental medicine and biology · 2025Review
- AI-driven strategies for advancing corneal cell therapy: a promising frontier.Frontiers in medicine · 2025Review
- Automated, aseptic sampling with small-volume capacity from microbioreactors for cell therapy process analysis.Frontiers in bioengineering and biotechnology · 2025Article
- Review
- Exploring bias risks in artificial intelligence and targeted medicines manufacturing.BMC medical ethics · 2024Article
- Noninvasive total counting of cultured cells using a home-use scanner with a pattern sheet.iScience · 2024Article
- Robotics-Driven Manufacturing of Cartilaginous Microtissues for Skeletal Tissue Engineering Applications.Stem cells translational medicine · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Although regenerative medicine products are at the forefront of scientific research, technological innovation, and clinical translation, their reproducibility and large-scale production are compromised by automation, monitoring, and standardization issues. To overcome these limitations, new technologies at software (e.g., algorithms and artificial intelligence models, combined with imaging software and machine learning techniques) and hardware (e.g., automated liquid handling, automated cell expansion bioreactor systems, automated colony-forming unit counting and characterization units, and scalable cell culture plates) level are under intense investigation. Automation, monitoring and standardization should be considered at the early stages of the developmental cycle of cell products to deliver more robust and effective therapies and treatment plans to the bedside, reducing healthcare expenditure and improving services and patient care.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.